Check whether continuing imatinib works after long GIST control
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies people with advanced or metastatic gastrointestinal stromal tumor (GIST) who have been on the drug imatinib for 10 years with stable, non-growing disease. The goal is to see how effective it is to keep imatinib going after this long period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have confirmed advanced/metastatic GIST and your tumor tests positive for a protein called c-KIT (CD117).
- Your disease is controlled—there has been no progression while you’ve been on imatinib.
- You have been taking imatinib daily at 300–400 mg for 10 years or longer, with very limited treatment breaks (no more than 12 months total, or no more than 3 consecutive months).
- You can do study visits and blood tests as scheduled and sign consent.
- You have overall good functioning (ECOG performance status 0–2, checked within 7 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
This study follows people who have been taking targeted cancer drugs (called TKIs) for advanced GIST for at least 2 years to understand how these long-term treatments affect quality of life, side effects, and daily living. Researchers want to learn what challenges patients face and how to better support them.
This trial tests a new drug called KQB198 combined with imatinib for people with advanced or metastatic gastrointestinal stromal tumor (GIST) that has a specific KIT or PDGFRA mutation. The goal is to see if this combination works better than imatinib alone as a first treatment.
This trial studies whether taking imatinib before surgery can shrink or control high-risk gastrointestinal stromal tumors (GIST). If you qualify, you would receive imatinib as “neoadjuvant” (before the operation) and then move on to planned surgery.
Hear when a new Metastatic Gastrointestinal Stromal Tumor (GIST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.